Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 178, Issue 4, Pages 321-329
Publisher
Bioscientifica
Online
2018-01-26
DOI
10.1530/eje-17-0996
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabergoline in acromegaly
- (2016) Emmanuelle Kuhn et al. Pituitary
- Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly: Experience from Acrostudy
- (2015) Pamela Freda et al. Endocrine Practice
- Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
- (2014) S. J. C. M. M. Neggers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
- (2014) John D. Carmichael et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Expert consensus document: A consensus on the medical treatment of acromegaly
- (2014) Andrea Giustina et al. Nature Reviews Endocrinology
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
- (2012) C. E. Higham et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination treatment with somatostatin analogues and pegvisomant in acromegaly
- (2011) S.J.C.M.M. Neggers et al. GROWTH HORMONE & IGF RESEARCH
- Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients
- (2011) Michael Madsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Place of Cabergoline in Acromegaly: A Meta-Analysis
- (2011) Laure Sandret et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
- (2010) Aart-Jan van der Lely et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR
- (2010) Lucio Vilar et al. Pituitary
- A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
- (2009) Peter J. Trainer et al. CLINICAL ENDOCRINOLOGY
- Successful use of weekly pegvisomant administration in patients with acromegaly
- (2009) C E Higham et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- ACROSTUDY: the first 5 years
- (2009) Peter J Trainer EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
- (2009) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
- (2008) Robert D. Murray et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search